SRRK - Scholar Rock Holding Corp Stock Price, Fair Value and News

14.53USD+0.57 (+4.08%)Market Closed

Market Summary

USD14.53+0.57

Market Closed

4.08%

SRRK Stock Price

View Fullscreen

SRRK RSI Chart

SRRK Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-6.82

Price/Sales (Trailing)

35.54

Price/Free Cashflow

-7.79

SRRK Price/Sales (Trailing)

SRRK Profitability

Return on Equity

-73.61%

Return on Assets

-53.3%

Free Cashflow Yield

-12.84%

SRRK Fundamentals

SRRK Revenue

Revenue (TTM)

33.2M

SRRK Earnings

Earnings (TTM)

-165.8M

Earnings Growth (Yr)

-17.5%

Earnings Growth (Qtr)

-8.89%

Breaking Down SRRK Revenue

Last 7 days

4.9%

Last 30 days

-5.9%

Last 90 days

-0.5%

Trailing 12 Months

128.5%

How does SRRK drawdown profile look like?

SRRK Financial Health

Current Ratio

8.8

Debt/Equity

0.22

Debt/Cashflow

-2.98

SRRK Investor Care

Shares Dilution (1Y)

49.79%

Diluted EPS (TTM)

-1.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	47.3M	42.7M	37.2M	33.2M
2021	15.1M	15.8M	18.2M	18.8M
2020	22.4M	21.3M	19.5M	15.4M
2019	0	0	0	20.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Scholar Rock Holding Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	peng katie	acquired	-	-	26,825	-
Feb 16, 2024	ho junlin	sold	-54,928	15.7432	-3,489	general counsel
Feb 16, 2024	myles edward h	sold	-74,685	15.7432	-4,744	coo & cfo
Feb 16, 2024	backstrom jay t.	sold	-182,842	15.7432	-11,614	chief executive officer
Feb 16, 2024	qatanani mo	sold	-39,546	15.7432	-2,512	chief scientific officer
Feb 16, 2024	parlavecchio caryn	sold	-59,052	15.7432	-3,751	chro
Feb 12, 2024	backstrom jay t.	acquired	-	-	214,285	chief executive officer
Feb 12, 2024	sacco tracey	acquired	-	-	49,285	chief commercial officer
Feb 12, 2024	myles edward h	acquired	-	-	53,570	coo & cfo
Feb 12, 2024	parlavecchio caryn	acquired	-	-	47,145	chro

Which funds bought or sold SRRK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	reduced	-34.48	-107,225	174,155	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	1,237	466,000	506,000	-%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	-308	5,257	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	8.00	69,571	3,498,410	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	-185,000	583,000	-%
Apr 24, 2024	Spire Wealth Management	unchanged	-	25,529	167,921	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	added	0.74	-40,053	788,651	0.04%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.12	-58,000	34,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	25.58	385,499	551,291	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	241,376	241,376	-%

Are Funds Buying or Selling SRRK?

Are funds buying SRRK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRRK

No. of Funds

Unveiling Scholar Rock Holding Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	12.3%	8,963,835	SC 13G/A
Feb 14, 2024	arch venture fund viii, l.p.	-	0	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	7,706,883	SC 13G/A
Feb 14, 2024	orbimed advisors llc	4.1%	2,960,000	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	polaris venture partners vi, l.p.	3.3%	2,406,309	SC 13G/A
Feb 09, 2024	artal international s.c.a.	17.4%	12,834,446	SC 13G/A
Jan 26, 2024	blackrock inc.	6.9%	4,962,597	SC 13G
Oct 18, 2023	samsara biocapital, l.p.	11.0%	7,853,413	SC 13D/A
Feb 14, 2023	bb biotech ag	4.1%	2,132,725	SC 13G/A

Recent SEC filings of Scholar Rock Holding Corp

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	PRE 14A	PRE 14A
Apr 11, 2024	4	Insider Trading
Mar 19, 2024	10-K	Annual Report
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	S-8	Employee Benefits Plan
Feb 21, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading

Peers (Alternatives to Scholar Rock Holding Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Scholar Rock Holding Corp News

Latest updates

Scholar Rock Holding Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	-	33,193	4,049	5,464	4,595	4,708	3,436	3,037	3,900	5,030	7,573	4,774	5,039	3,106
Operating Expenses	-7.8%	40,428	43,862	43,147	40,126	39,413	42,541	34,868	31,915	29,540	26,655	23,362	22,724	19,920	21,880	18,425	14,809
S&GA Expenses	3.3%	10,815	10,470	11,074	10,760	10,362	11,276	9,265	9,366	7,760	8,272	6,365	5,822	5,856	6,181	4,710	4,070
R&D Expenses	-11.3%	29,613	33,392	32,073	29,366	29,051	31,265	25,603	22,549	21,780	18,383	16,997	16,902	14,064	15,699	13,715	10,739
Interest Expenses	12.0%	1,340	1,196	1,024	812	588	502	501	491	244	-	-	-	-	1.00	-942	948
Net Income	9.3%	-39,255	-43,297	-44,000	-7,950	-35,914	-37,507	-30,707	-27,671	-26,571	-23,561	-19,281	-17,070	-11,573	-16,147	-12,525	-10,755
Net Income Margin	-15.1%	-4.05*	-3.52*	-2.94*	-2.37*	-7.00*	-6.73*	-6.88*	-6.44*	-	-	-	-	-	-	-	-
Free Cashflow	-9.5%	-29,024	-26,510	-35,216	-43,008	-32,997	-37,388	-32,796	-28,856	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	24.1%	311	251	285	315	358	390	424	266	304	298	332	361	388	163	156	176	196	189	197	171	181
Current Assets	26.1%	288	228	260	287	328	358	389	229	265	258	290	318	344	119	145	164	185	179	188	162	178
Cash Equivalents	50.7%	102	68.00	108	151	103	133	306	100	215	176	207	159	163	56.00	115	95.00	39.00	33.00	114	67.00	115
Net PPE	-12.9%	5.00	5.00	6.00	7.00	7.00	8.00	9.00	9.00	10.00	10.00	9.00	9.00	8.00	6.00	4.00	4.00	4.00	4.00	3.00	4.00	3.00
Liabilities	3.4%	86.00	83.00	82.00	86.00	98.00	97.00	95.00	95.00	132	111	115	120	128	100	74.00	77.00	83.00	67.00	68.00	73.00	75.00
Current Liabilities	22.5%	33.00	27.00	24.00	26.00	36.00	34.00	40.00	33.00	64.00	65.00	67.00	70.00	43.00	33.00	33.00	27.00	33.00	33.00	32.00	34.00	31.00
Short Term Borrowings	-	1.00	-	-	-	-	1.00	12.00	7.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-2.6%	49.00	50.00	50.00	50.00	50.00	50.00	39.00	44.00	48.00	25.00	25.00	25.00	25.00	-	-	-	-	-	-	-	0.00
LT Debt, Non Current	-2.6%	49.00	50.00	50.00	50.00	50.00	50.00	39.00	44.00	48.00	25.00	25.00	25.00	25.00	-	-	-	-	-	-	-	-
Shareholder's Equity	34.3%	225	168	203	229	260	293	330	171	172	187	217	241	261	63.00	82.00	99.00	113	122	129	98.00	107
Retained Earnings	-7.3%	-676	-630	-587	-550	-510	-471	-428	-384	-376	-340	-302	-272	-244	-217	-194	-174	-157	-146	-130	-117	-106
Additional Paid-In Capital	13.0%	901	798	790	779	772	766	758	556	548	527	519	512	505	281	276	273	271	268	259	215	213
Shares Outstanding	35.0%	76.00	56.00	55.00	52.00	52.00	79.00	42.00	37.00	35.00	37.00	37.00	36.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	158	-	-	-	110	-	-	-	532	-	-	-	340	-	-	-	185	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-15.7%	-37,349	-32,273	-32,550	-43,054	-28,907	-26,483	-34,739	-42,565	-32,455	-35,977	-31,813	-26,544	-19,685	-23,395	-19,827	2,636	-16,067	-15,112	-16,406	-15,530	55,094
Share Based Compensation	-3.5%	6,951	7,203	6,818	6,170	6,165	7,917	6,791	6,828	6,096	6,154	6,226	4,673	2,530	4,036	2,395	2,214	1,852	2,688	1,814	1,618	2,154
Cashflow From Investing	-196.6%	-25,128	-8,473	-15,241	89,983	77.00	-145,721	44,522	-70,576	29,458	3,283	79,017	22,557	-122,641	-35,874	38,926	56,091	21,209	-72,169	21,102	-32,378	-60,939
Cashflow From Financing	34374.6%	96,529	280	4,689	1,076	-970	-451	195,772	481	39,701	1,906	607	2,737	246,457	368	595	399	818	6,124	42,098	-157	16,928

SRRK Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenue		$ 33,193
Operating expenses:
Research and development	$ 121,900	124,444
General and administrative	49,395	43,119
Total operating expenses	171,295	167,563
Loss from operations	(171,295)	(134,370)
Other income (expense), net	5,506	(132)
Net loss	$ (165,789)	$ (134,502)
Net loss per share, basic (in dollars per share)	$ (1.99)	$ (2.26)
Net loss per share, diluted (in dollars per share)	$ (1.99)	$ (2.26)
Weighted average common shares outstanding, basic (in shares)	83,347,086	59,611,656
Weighted average common shares outstanding, diluted (in shares)	83,347,086	59,611,656
Comprehensive loss:
Net loss	$ (165,789)	$ (134,502)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	976	(849)
Total other comprehensive income (loss)	976	(849)
Comprehensive loss	$ (164,813)	$ (135,351)

SRRK Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 101,855	$ 103,275
Marketable securities	178,083	212,086
Prepaid expenses and other current assets	8,256	12,663
Total current assets	288,194	328,024
Property and equipment, net	4,600	7,384
Operating lease right-of-use asset	11,417	18,543
Restricted cash	2,407	2,498
Other long-term assets	4,417	1,719
Total assets	311,035	358,168
Current liabilities:
Accounts payable	3,465	3,994
Accrued expenses	20,449	24,321
Operating lease liability	7,408	7,852
Short-term debt	1,334
Other current liabilities	85	222
Total current liabilities	32,741	36,389
Long-term portion of operating lease liability	4,392	11,800
Long-term debt	48,684	49,744
Total liabilities	85,817	97,933
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022; no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.001 par value; 150,000,000 shares authorized; 75,979,495 and 51,672,579 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	76	52
Additional paid-in capital	901,471	771,699
Accumulated other comprehensive income (loss)	92	(884)
Accumulated deficit	(676,421)	(510,632)
Total stockholders' equity	225,218	260,235
Total liabilities and stockholders' equity	$ 311,035	$ 358,168

About Scholar Rock Holding Corp

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Jay T. Backstrom M.D., M.P.H.
WEBSITE	https://scholarrock.com
INDUSTRY	Biotechnology
EMPLOYEES	114

Scholar Rock Holding Corp Frequently Asked Questions

What is the ticker symbol for Scholar Rock Holding Corp? What does SRRK stand for in stocks?

SRRK is the stock ticker symbol of Scholar Rock Holding Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Scholar Rock Holding Corp (SRRK)?

As of Fri Apr 26 2024, market cap of Scholar Rock Holding Corp is 1.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRRK stock?

You can check SRRK's fair value in chart for subscribers.

What is the fair value of SRRK stock?

You can check SRRK's fair value in chart for subscribers. The fair value of Scholar Rock Holding Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Scholar Rock Holding Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRRK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Scholar Rock Holding Corp a good stock to buy?

The fair value guage provides a quick view whether SRRK is over valued or under valued. Whether Scholar Rock Holding Corp is cheap or expensive depends on the assumptions which impact Scholar Rock Holding Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRRK.

What is Scholar Rock Holding Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, SRRK's PE ratio (Price to Earnings) is -6.82 and Price to Sales (PS) ratio is 35.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRRK PE ratio will change depending on the future growth rate expectations of investors.